“The new findings come from prespecified analyses of Novo Nordisk’s multicenter, randomized SELECT trial, which showed that compared with placebo, weekly semaglutide 2.4 mg significantly reduced the risk for cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) over a mean of 39.8 months’ follow-up in 17,604 patients aged ≥ 45 years who had overweight/obesity and established CVD but not diabetes…

In the new analysis, presented on November 3 at The Obesity Society’s Obesity Week 2024 conference, those treated with semaglutide were 11% less likely to be hospitalized for any reason. Hospitalizations for cardiovascular causes were reduced by 17%, but those on semaglutide also had significant reductions in hospitalizations for other causes, ranging from 15% to 24%.”

From Medscape.